Project Grant R01AI189503
Award Date
5/1/25
Completion Date
4/30/30
Dollars Obligated
$748K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Durham, NC 27710, USA
Similar Awards
This $802,798 federal Project Grant was awarded on July 2, 2024 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports the development of a novel class of antibiotics called Biamyxins (BMX) that target multidrug-resistant Gram-negative bacterial infections, which are a leading cause of healthcare-associated infections (HAIs) in the U.S. The goal is to identify a lead development candidate...
The federal Project Grant award R01AI187556 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $749,417.00 in funding to President and Fellows of Harvard College from November 2024 through October 2029. The research project aims to synthesize and evaluate novel antibiotic compounds targeting the lipoprotein transport pathway in Gram-negative bacteria, including multidrug-resistant E. coli and K....
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is for the development of novel antibiotic therapies targeting Clostridioides difficile infection (CDI). The $754,446 award aims to: Optimize a lead series of inhibitors targeting the essential bacterial enzyme FabK, with the goal of improving antimicrobial potency and selectivity against C. difficile. Identify new chemical...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $661,387.00 to Emory University to conduct research on the regulation and mechanism of RND-mediated antibiotic efflux in Pseudomonas bacteria. The goal is to generate a comprehensive understanding of the MexXY-OprM efflux system, including the molecular basis of gene regulation and substrate selection, in order to...
This $241,500 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will develop a high-throughput screening approach to discover novel protein-based efflux pump inhibitors (EPIs). The goal is to expedite the discovery of EPIs that can block antibiotic resistance mechanisms in pathogenic bacteria, which pose a global health emergency. The project will establish a robust assay to screen...
This Project Grant award, with ID R21AI178088, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding of $424,076 supports research to develop new computational methods for designing macrocyclic inhibitors of the bacterial type I signal peptidase (SPase I), a validated target for antibiotic development. The project will leverage physics-based and deep learning-based peptide design...
This $637,729 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to President and Fellows of Harvard College, operating as Harvard Medical School. The award period runs from December 13, 2024 to November 30, 2029. The grant supports research to investigate the molecular mechanisms underlying the activation and regulation of essential bacterial cell wall synthase enzymes, which are...
This $714,053 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Research Foundation For The State University Of New York. The purpose of the grant is to develop an optimized multi-phage (n-phage) cocktail therapy and a novel physiologically-based pharmacokinetic (PBPK) model to improve the translation of phage-based treatments for extensively-drug resistant Pseudomonas...
This $195,625 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to structurally and functionally characterize phosphoethanolamine (PEtN) transferase enzymes that modify bacterial lipid A, resulting in resistance to cationic antimicrobial peptides like colistin. The research aims to develop inhibitory strategies and quantitative in vitro assays to evaluate inhibitors...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Rowan University a $474,363 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel, daptomycin-inspired antimicrobial peptides using non-canonical amino acids. The goal is to create peptide molecules that recapitulate the key antimicrobial properties of daptomycin, including calcium binding and lipid membrane disruption, while improving resistance to host degradation and...